Trial Profile
NANT 2011- 01: Randomized Phase II Pick the Winner Study of 131I-MIBG, 131I-MIBG With Vincristine and Irinotecan, or 131I-MIBG With Vorinostat for Resistant/Relapsed Neuroblastoma
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 22 Aug 2019
Price :
$35
*
At a glance
- Drugs Iobenguane (Primary) ; Irinotecan; Vincristine; Vorinostat
- Indications Neuroblastoma
- Focus Therapeutic Use
- Acronyms NANT2011-01
- 19 Aug 2019 Planned End Date changed from 1 Dec 2019 to 1 Jul 2020.
- 19 Aug 2019 Planned primary completion date changed from 1 Jun 2019 to 1 Jan 2020.
- 01 Aug 2018 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.